Integra LifeSciences Holdings Corporation filings document regulatory disclosures for a Nasdaq-listed medical technology issuer with common stock registered under Section 12(b). Forms 8-K cover operating results and financial condition, including GAAP-to-non-GAAP reconciliations for organic revenue, adjusted EBITDA, adjusted earnings per share, net debt and free cash flow, as well as guidance-related disclosures.
Proxy and material-event filings address board elections, shareholder voting, executive compensation and equity incentive plan amendments. Other filings describe leadership appointments, employment and severance arrangements, and financing matters such as the company’s accounts receivable securitization facility used for liquidity and ongoing business funding.
Poul Mojdeh reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP reported that President & CEO Poul Mojdeh received a grant of 343,393 restricted stock units tied to common stock. The award vests in three equal annual installments on the first, second, and third anniversaries of the March 11, 2026 grant date.
The units are structured as deferred compensation, to be delivered within 30 days after the first business day following six months after her separation of service. Vesting may accelerate if employment ends due to death, disability, or a qualifying termination within 24 months after a change in control. Following this grant, her reported holdings in this RSU award total 445,691 units.
Hutchinson Michael Damon reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael Damon Hutchinson, EVP and Chief Legal Officer, received a grant of 70,305 restricted stock units tied to common stock. This award will vest 33% on the first and second anniversaries and 34% on the third anniversary of the March 11, 2026 grant date, increasing his directly held RSU position to 159,911 units.
Integra LifeSciences Holdings Corporation filed a shelf registration on Form S-3 registering common stock, preferred stock, debt securities, warrants, purchase contracts and units for possible future offers. The prospectus permits offers "from time to time after the effective date" and states supplements will disclose specific amounts, prices and terms.
The company notes its common stock trades on Nasdaq under the symbol IART and cites a closing price of $11.59 per share on February 25, 2026. The filing also discloses that as of December 31, 2025 there were 77,886,634 shares of common stock issued and 14,398,724 shares designated as treasury stock.
Integra LifeSciences Holdings Corporation files its Annual Report describing a global medical technology business focused on neurosurgery, surgical instruments, ENT and regenerative tissue products. The Codman Specialty Surgical segment provides about 70% of revenue, with Tissue Technologies contributing about 30%.
The company highlights its leadership in neurosurgery, advanced wound care and soft-tissue reconstruction, supported by a broad R&D program and global sales network. It is pursuing PMA approvals for SurgiMend and DuraSorb in breast reconstruction, targeted for 2026, and is relocating and expanding manufacturing capacity, including a new Braintree, Massachusetts facility.
Integra outlines extensive quality and regulatory initiatives, including a Compliance Master Plan to upgrade its quality management systems and respond to FDA expectations. The report also details competitive dynamics, reimbursement and healthcare reform pressures, and comprehensive global regulatory and data privacy obligations. As of June 30, 2025, non‑affiliate market value was about $925.1 million, with 77,937,208 common shares outstanding as of February 25, 2026.
Integra LifeSciences reported flat-to-modest growth in 2025 but a large GAAP loss driven by non-cash charges. Full-year revenue was $1,635.2 million, up 1.5%, while GAAP earnings per diluted share fell to $(6.74) from $(0.09), mainly due to a $511 million goodwill impairment recorded in the second quarter.
On an adjusted basis, 2025 EBITDA was $317.5 million (19.4% margin), slightly below 2024, and adjusted earnings per diluted share declined to $2.23 from $2.56. Free cash flow for the year was negative at $(31.1) million, and net debt stood at $1.60 billion with a total leverage ratio of 4.5x and liquidity of about $516 million.
In the fourth quarter, revenue was $434.9 million, down 1.7%, with organic revenue down 2.5%. GAAP EPS was $(0.02), and adjusted EPS was $0.83. For 2026, the company guides revenue to $1,662–$1,702 million and adjusted EPS to $2.30–$2.40, with Q1 revenue of $375–$390 million and adjusted EPS of $0.37–$0.45.
Integra LifeSciences Holdings Corp received an amended ownership report from institutional investor Fuller & Thaler Asset Management, Inc. as of 12/31/2025. Fuller & Thaler reports beneficial ownership of 3,636,359.96 shares of Integra common stock, representing 4.67% of the class.
The firm has sole power to vote 3,583,652.96 shares and sole power to dispose of 3,636,359.96 shares, with no shared voting or dispositive power. Fuller & Thaler certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Integra.
Integra LifeSciences Holdings Corp reported an equity grant to executive officer Michael Damon Hutchinson, EVP, Chief Legal Officer & Secretary. On 02/02/2026, he received 89,606 restricted stock units at a price of $0 per unit, held as a direct interest.
The filing states that this restricted stock unit award will vest 100% on the second anniversary of the grant date of 02/02/2026, meaning the award is fully time‑based and contingent on continued service through that future vesting date.
Integra LifeSciences Holdings Corp executive Michael Damon Hutchinson filed an initial ownership report showing no securities beneficially owned. The Form 3 identifies him as EVP, Chief Legal Officer and Secretary of Integra LifeSciences, and confirms that, as of the event date, he did not hold any direct or indirect equity or derivative securities of the company.
Integra LifeSciences Holdings Corp President & CEO Mojdeh Poul reported routine equity compensation activity. On January 6, 2026, 848 and 542 shares of common stock were acquired at $0 per share upon the vesting and settlement of corresponding restricted stock units.
On the same date, 848 and 542 common shares were disposed of at $13.13 per share in transactions coded "F", reflecting shares withheld or sold to cover taxes. Following these transactions, the report shows no directly held common stock, while Ms. Poul continues to hold restricted stock unit awards, with post-transaction amounts reported as 102,840 and 102,298 units in two separate grants. A footnote explains that these awards vest in three equal annual installments starting January 6, 2026 and are scheduled for deferred delivery after her separation from service.
Integra LifeSciences Holdings Corporation adopted a renewed change in control severance program for certain senior executives, effective January 1, 2026. The program applies if an executive is terminated without cause or resigns for good reason within two years after a change in control that occurs by December 31, 2026.
Covered leaders include CFO Lea Knight and business presidents Robert T. Davis, Jr., Michael McBreen, and Harvinder Singh. On a qualifying termination, they may receive a lump sum of 1.5 times their salary plus target bonus, or 2 times for Ms. Knight, a pro rata target bonus for the year of termination, subsidized COBRA premiums for up to 18 months, up to 12 months of outplacement services, and any earned but unpaid prior-year bonus. Benefits require a release of claims and are subject to a “best pay cap” that can reduce payments to mitigate excise taxes. The program runs through December 31, 2026, with automatic extensions after a change in control or qualifying termination until all obligations are met.